Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Arvelle Therapeutics GmbH

https://www.arvelletx.com/

Latest From Arvelle Therapeutics GmbH

Ontozry Wins English Funding For Drug-Resistant Epilepsy

Heath technology assessment body NICE estimates that around 17,000 patients would be eligible for treatment with Arvelle’s drug.

United Kingdom Health Technology Assessment

Rising US Sales, EU Milestone Boost SK Bio's Q1

After strong first-quarter results, SK Biopharmaceuticals expects sales growth to accelerate as the US marketing environment improves and as EU sales of epilepsy drug cenobamate begin.

Neurology South Korea

New EU Approvals

The Pink Sheet's list of EU centralized approvals of new active substances has been updated to include three new products, including GlaxoSmithKline's Jemperli (dostarlimab), which is the first anti-PD-1 therapy approved for recurrent or advanced endometrial cancer. 

Approvals Europe

EU Approval Verdicts Near For A Bumper Crop Of New Drugs

Novartis, Arvelle, AstraZeneca and Incyte are among a raft of drug sponsors who should find out shortly whether the European Medicines Agency will vote in favor of approving their products for use in the EU.

Europe Approvals
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
UsernamePublicRestriction

Register